Approved Study Database

Ref. No. Scientific Title Principal investigator
2010.250 HMGB1: a danger signal molecule of the innate immune response for the immunopathogenesis of systemic lupus erythematosus Professor TAM Lai Shan
2011.547 The role of Receptor for Advanced Glycation End Products (RAGE) in the pathogenesis of systemic Lupus erythematosus (SLE) Professor TAM Lai Shan
2008.475 Innate pathogen recognition in systemic lupus erythematosus: Toll-like receptors and NOD-like receptors Prof Tam Lai Shan
2010.191 Human Papillomavirus infection and cervical intraepithelial neoplasia in patients with systemic lupus erythematosus- the role of toll-like receptors Professor TAM Lai Shan
2011.031 The role of HMGB1 in the pathogenesis of systemic lupus erythematosus Professor TAM Lai Shan
2009.583 Function and expression profile of the nucleotide-blinding and oligoerization domain (NOD)-2 receptors in systemic lupus erythematosus Prof Tam Lai Shan
2008.344 Premature Atherosclerosis in Early Rheumatoid Arthritis Prof Tam Lai Shan
2008.161 SERAPHIN-OL: Study with An ERA in Pulmonary Arterial Hypertension to Improve Clinical Outcome (Open Label) – Long-term Single-arm Open-label Extension Study of the SERAPHIN study, to Assess the Safety and Tolerability of ACT-064922 in Patients with Symptomatic Pulmonary Arterial Hypertension Prof. TAM Lai Shan
2008.160 SERAPHIN: Study with Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome Prof Tam Lai Shan
2008.159 A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-Positive Systemic Lupus Erythematosus Patients with Active Disease Who Participated in Study SL0007 Asso. Prof. TAM Lai Shan
2012.559 A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF-α antagonists Prof. TAM Lai Shan
2012.558 An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus Professor Tam Lai Shan
2012.557 A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab Prof. TAM Lai Shan
2008.343 The Chinese University of Hong Kong Early Arthritis Study Prof Tam Lai Shan
2012.476 Alteration in bone density and microstructure in early rheumatoid arthritis and its relationship with bone erosion: A one-year study by HR-pQCT and MRI Prof. TAM Lai Shan
2014.082 A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects with Lupus Nephritis Prof. TAM Lai Shan
2007.486 A Double-blind, Randomized, Placebo-control Trial to Assess the Effects of Hydroxychloroquine on Progression of Carotid Artery Intimal-Medial Thickening in Psoriatic Arthritis Ms Tam Lai Shan
2008.391 A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), A Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057 Prof. TAM Lai Shan
2012.200 A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus Prof. TAM Lai Shan
2010.491 Effect of early intensive treatment in patients with recent-onset rheumatoid arthritis Prof. TAM Lai Shan
2010.056 Effect of anti-TNF Professor TAM LAI SHAN
2012.007 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis Prof. TAM Lai Shan
2013.568 A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with ankylosing spondylitis. Prof. TAM Lai Shan
2014.167 Exploiting the immunomodulatory and anti-inflammatory role of IL35 to modulate inflammation and autoreactive B cell activation in rheumatoid arthritis Prof. TAM Lai Shan
2011.483 Effect of treat-to-target strategies aiming at remission compared with minimal disease activity on arterial stiffness in early rheumatoid arthritis - a randomized controlled study Prof. TAM Lai Shan
2011.378 A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4) Prof. TAM Lai Shan
2013.470 A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA) Prof Tam Lai Shan
2019.063 Effects of tight-control strategy with rosuvastatin on progression of subclinical carotid and coronary atherosclerosis in psoriatic arthritis- a prospective cohort study Prof. TAM Lai Shan
譚麗珊
2018.144 Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of fracture risk in patients with glucocorticoid-induced osteoporosis Prof. TAM Lai Shan
譚麗珊
2019.224 Effects of achieving SDAI remission on joint space outcomes progression in early rheumatoid arthritis: an HR-pQCT study Prof. TAM Lai Shan
譚麗珊
2018.225 The APLAR Spondyloarthritis (SpA) Registry Prof. TAM Lai Shan
譚麗珊
2019.247 Survival benefit of statin use in patients with immune mediated inflammatory diseases in Hong Kong - A population-based study Prof. TAM Lai Shan
2019.650 Effects of tight-control strategy with and without rosuvastatin on progression of subclinical coronary and carotid atherosclerosis in psoriatic arthritis- a randomized placebo-controlled study Prof. TAM Lai Shan
譚麗珊
2019.180 The microbiome study in psoriasis and psoriatic arthropathy patients in Hong Kong Prof. TAM Lai Shan
譚麗珊
2020.141 Quantification of erosion, joint space width and new bone formation using deep learning-based approaches Prof. TAM Lai Shan
譚麗珊
2019.264 Incidence of and associated factors of infective complications in rheumatology patients taking DMARDs Dr. TAM Lai Shan
2020.128 Portable integrated diagnostic platform for chronic auto-immune diseases Prof. TAM Lai Shan
譚麗珊
2018.417 Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using tofacitinib Prof. TAM Lai Shan
2020.129 Vascular effects of achieving low disease activity in axial spondyloarthritis - a 2-year prospective cohort study Prof. TAM Lai Shan
譚麗珊
2019.401 Immunological role of the ILC2-B lymphocyte regulatory axis in systemic lupus erythematosus Prof. TAM Lai Shan
譚麗珊
2019.540 A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Dr. TAM Lai Shan
譚麗珊
2020.519 Cardiovascular events in axial spondyloarthritis Prof. TAM Lai Shan
譚麗珊
2020.617 Subclinical atherosclerosis in axial spondyloarthritis- a cross-sectional study Prof. TAM Lai Shan
譚麗珊
2020.530 5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients who received Treat-to-Target Management: a population-based cohort study Prof. TAM Lai Shan
譚麗珊
2020.704 Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with rheumatoid arthritis Prof. TAM Lai Shan
2020.516 CUHK Rheumatology Research Centre Imaging Database of Rheumatic Diseases Prof. TAM Lai Shan
譚麗珊
2019.573 Subclinical gut inflammation and gut microbiome in axial spondyloarthritis patients in Hong Kong Prof. TAM Lai Shan
譚麗珊
2023.189 Survey of cardiovascular disease Risk Factors in Psoriatic Arthritis Prof. TAM Lai Shan
2021.187 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus Prof. TAM Lai Shan
譚麗珊 教授
2023.306 Low-dose computed tomography for the detection of structural changes in axial psoriatic arthritis Prof. TAM Lai Shan

Page 62 of 262.